Tralokinumab-ldrm is approved for the treatment of moderate-to-severe AD in adult and adolescent patients 12 years and older in the European Union, Canada, Great Britain, the United Arab Emirates, ...
Christina Gentry, DVM, DACVD, discusses how veterinary practitioners can work with these specialists and learn more about dermatology.